Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Circulating Nucleic Acids and Circulating Rare Cells: Liquid Biopsy for Early Cancer Detection

Ryan Dittamore's Biography



Ryan Dittamore, Vice President, Translational Research and Clinical Affairs, Epic Sciences

Ryan Dittamore is the Vice President of Translational Research & Clinical affairs at Epic Sciences. He is a recognized molecular diagnostics leader with extensive scientific, medical and business experience in developing and commercializing cancer diagnostics. At Epic Sciences, Mr. Dittamore leads translational research and clinical affairs initiatives to develop clinical validity and utility for new products that address critical unmet medical needs in oncology. This included the translational research and clinical development of Epic AR-V7 test, the first predictive test in prostate cancer, and first liquid biopsy test with novel clinical utility. Additionally, he leads the product development roadmap which includes initiation and execution of numerous oncology clinical trials with top academic/government investigators as well as strategic partnerships across >60 clinical trials with 37 biopharmaceutical companies.

Ryan Dittamore’s background includes a diverse set of roles spanning over 20 years in the diagnostic and life science industries. He has been involved in research, product development, marketing, business development, sales and global channel management. Before his tenure at Epic Sciences, Mr. Dittamore served as Director of Medical Innovation and Disease Lead for Genitourinary (GU) Cancers at Ventana Medical Systems (Roche Tissue Diagnostics). He led translational research, product development, and marketing efforts for GU medical value products. His work has led to numerous novel abstracts, publications, and patents towards improving patient outcomes.

Ryan Dittamore Image

Development of Predictive CTC Tests and Validation of their Clinical Utility for Therapeutic Benefit

Thursday, 29 March 2018 at 17:30

Add to Calendar ▼2018-03-29 17:30:002018-03-29 18:30:00Europe/LondonDevelopment of Predictive CTC Tests and Validation of their Clinical Utility for Therapeutic BenefitSELECTBIOenquiries@selectbiosciences.com

The development of liquid biopsy tests to inform clinical decisions in metastatic cancers is an unmet medical need.  The presentation will overview novel test development, analytic validation, clinical development and demonstration of clinical utility in multiple clinical decision points in metastatic cancers.


Add to Calendar ▼2018-03-28 00:00:002018-03-29 00:00:00Europe/LondonCirculating Nucleic Acids and Circulating Rare Cells: Liquid Biopsy for Early Cancer Detection SELECTBIOenquiries@selectbiosciences.com